ScreenerHero
SFZNSiegfried Holding AG
SWX · CH · Healthcare · Drug Manufacturers - Specialty & Generic · siegfried.ch
80.25CHF+2.69%Mkt Cap: 4.01B $P/E: 20.90

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap4.01B $
Enterprise Value4.44B $
Revenue (TTM)1.52B $
Gross Profit404.01M $
Net Income (TTM)192.49M $
Revenue/Share34.63 USD
Last Price80.25 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees3.9K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)20.90
P/E (Forward)17.05
PEG1.50
EV/EBITDA12.64
EV/Revenue2.93
P/S2.66
P/B3.13
EPS (TTM)3.84
EPS (Forward)4.73
52W Range
65.0542% of range101.60
52W High101.60 CHF
52W Low65.05 CHF
Profitability
Gross Margin26.66%
Oper. Margin18.83%
EBITDA Margin23.21%
Profit Margin12.70%
ROE14.95%
ROA7.83%
Growth
Revenue Growth5.00%
Earnings Growth16.00%
Cash Flow & Leverage
Operating CF260.40M $
CapEx (TTM)264.18M $
FCF Margin-1.57%
FCF Yield-0.59%
Net Debt538.02M $
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity51.01
Current Ratio2.00
Quick Ratio1.14
Book Value/Sh25.75 CHF
Cash/Share2.369 CHF
Dividends
Fwd Div Rate0.4000 CHF
Trail. Div Rate0.4000 CHF
Div. Yield0.51%
5Y Avg Yield0.72%
Payout Ratio9.90%
Ex-Div DateApr 28, 2026
Pay DateApr 24, 2025
Splits
Last Split10:1
Split DateApr 28, 2025
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)99.42 CHF
Upside (mean)+23.9%
Target Range77.00 CHF – 130.00 CHF
CHF77.00+23.9% to meanCHF130.00
# Analysts12
Ownership
Shares Out.43.81M
Float39.80M
Insiders13.23%
Institutions54.80%
Technical
SMA 5073.46 (+9.2%)
SMA 20078.17 (+2.7%)
Beta0.81
S&P 52W Chg18.16%
Avg Vol (30d)81.43K
Avg Vol (10d)94.64K
Technical Indicators
RSI (14)57.6
MACD1.3561
MACD Signal1.2767
MACD Hist.+0.0794
BB Upper82.10 CHF
BB Middle76.13 CHF
BB Lower70.16 CHF
BB Width15.69%
ATR (14)2.183 CHF
Vol Ratio (20d)1.33x